Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.

about

Unanticipated Cardiotoxicity Associated with Targeted Anticancer Therapy in Patients with Hematologic Malignancies Patients: Natural History and Risk Factors.

P2860

Q48206067-1C374835-84A6-44EC-8EFF-DD781D060CBB

P2860

Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.

Item

http://www.wikidata.org/entity/Q38944823

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Beyond Anthracyclines: Preempt ...... for Hematologic Malignancies.

@en

type

Item

label

Beyond Anthracyclines: Preempt ...... for Hematologic Malignancies.

@en

prefLabel

Beyond Anthracyclines: Preempt ...... for Hematologic Malignancies.

@en

P1476

Beyond Anthracyclines: Preempt ...... for Hematologic Malignancies.

@en

P2093

Basak Basdag

http://www.w3.org/2001/XMLSchema#string

Javid Moslehi

http://www.w3.org/2001/XMLSchema#string

Nishitha M Reddy

http://www.w3.org/2001/XMLSchema#string

Tarsheen K Sethi

http://www.w3.org/2001/XMLSchema#string

P2860

Ibrutinib in previously treated Waldenström's macroglobulinemia.

Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells

Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.

P2888

s11899-017-0369-y

P304

257-267

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11899-017-0369-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nirmanmoh Bhatia

P577

2017-02-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1083862542

http://www.w3.org/2001/XMLSchema#string

P698

28233150

http://www.w3.org/2001/XMLSchema#string

Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.

about

P2860

P2860

Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698